<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00740805</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00262</org_study_id>
    <secondary_id>NCI-2009-00262</secondary_id>
    <secondary_id>CDR0000600234</secondary_id>
    <secondary_id>050803</secondary_id>
    <secondary_id>050803</secondary_id>
    <secondary_id>7998</secondary_id>
    <secondary_id>P30CA072720</secondary_id>
    <secondary_id>U01CA132194</secondary_id>
    <secondary_id>U01CA099118</secondary_id>
    <secondary_id>UM1CA186716</secondary_id>
    <nct_id>NCT00740805</nct_id>
  </id_info>
  <brief_title>Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Phase I Study of ABT-888 in Combination With Cyclophosphamide in Solid Tumors or Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of veliparib, cyclophosphamide, and&#xD;
      doxorubicin hydrochloride when given together in treating patients solid tumors or&#xD;
      non-Hodgkin lymphoma that has spread to other areas of the body or cannot be removed by&#xD;
      surgery. Veliparib may stop the growth of cancer cells by blocking some of the enzymes needed&#xD;
      for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and doxorubicin&#xD;
      hydrochloride, work in different ways to stop the growth of cancer cells, either by killing&#xD;
      the cells, by stopping them from dividing, or by stopping them from spreading. Giving&#xD;
      veliparib, cyclophosphamide, and doxorubicin hydrochloride may kill more cancer cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Identify the maximally tolerated dose (MTD) and dose limiting toxicity (DLT) of&#xD;
      cyclophosphamide when combined with escalating doses of ABT-888 (veliparib).&#xD;
&#xD;
      II. Identify the maximally tolerated dose (MTD) and dose limiting toxicity (DLT) of&#xD;
      cyclophosphamide and doxorubicin (doxorubicin hydrochloride) when combined with escalating&#xD;
      doses of ABT-888.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Evaluate any effect of ABT-888 on the systemic clearance of parent cyclophosphamide and&#xD;
      the dose normalized area under the curve (AUC) of 4-hydroxy (4-OH) cyclophosphamide when used&#xD;
      in combination, using historical single-agent cyclophosphamide and 4-OH data.&#xD;
&#xD;
      II. Evaluate any effect of cyclophosphamide administration on the systemic pharmacokinetics&#xD;
      of ABT-888 and its primary metabolite A-925088 (M8), by comparing pharmacokinetic (PK)&#xD;
      parameters of ABT-888 on day 1 (before cyclophosphamide) and day 3 (with cyclophosphamide&#xD;
      administration); PK samples for analysis will not be collected from patients enrolled after&#xD;
      2/15/2012.&#xD;
&#xD;
      III. Evaluate inhibition of poly (adenosine diphosphate [ADP] ribose) polymerase (PARP) using&#xD;
      an immunoassay designed to measure PAR levels in baseline and on-study peripheral blood&#xD;
      mononuclear cells (PBMC) samples; PBMC samples for PAR analysis will not be collected from&#xD;
      patients enrolled after 2/15/2012.&#xD;
&#xD;
      IV. Evaluate gamma H2A histone family, member X (H2AX) at baseline and on-study circulating&#xD;
      tumor cell samples to evaluate the point of maximal deoxyribonucleic acid (DNA) damage from&#xD;
      the combination of cyclophosphamide and doxorubicin with ABT-888.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of veliparib and cyclophosphamide.&#xD;
&#xD;
      GROUP I: Patients receive veliparib orally (PO) every 12 hours on days 1-4 and&#xD;
      cyclophosphamide intravenously (IV) over 60 minutes on day 3.&#xD;
&#xD;
      GROUP II: Patients receive veliparib PO every 12 hours on days 1-4, cyclophosphamide IV over&#xD;
      60 minutes on day 3, and doxorubicin hydrochloride IV over 15 minutes on day 3.&#xD;
&#xD;
      GROUP III: Patients receive veliparib PO every 12 hours on days 1-7, cyclophosphamide IV over&#xD;
      60 minutes on day 1, and doxorubicin hydrochloride IV over 15 minutes on day 1.&#xD;
&#xD;
      GROUP IV: Patients receive veliparib PO every 12 hours on days 1-14, cyclophosphamide IV over&#xD;
      60 minutes on day 1, and doxorubicin hydrochloride over 15 minutes on day 1.&#xD;
&#xD;
      In all groups, courses repeat every 21 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 18, 2008</start_date>
  <completion_date type="Anticipated">October 7, 2022</completion_date>
  <primary_completion_date type="Actual">September 3, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD, defined as the dose level that no more than 2/6 or 1/3 patients experience DLT and at least 2/3 or 3/6 patients treated with next higher dose level will have had DLT</measure>
    <time_frame>21 days</time_frame>
    <description>Graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pharmacokinetic parameters</measure>
    <time_frame>Day 1, course 1 to day 1, course 2</time_frame>
    <description>A two way analysis of variance model will be used to compare the PK parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gammaH2AX levels (quantification of the time point of maximal DNA damage)</measure>
    <time_frame>Baseline to up to day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Ann Arbor Stage III Non-Hodgkin Lymphoma</condition>
  <condition>Ann Arbor Stage IV Non-Hodgkin Lymphoma</condition>
  <condition>Solid Neoplasm</condition>
  <arm_group>
    <arm_group_label>Treatment (veliparib, cyclophosphamide, doxorubicin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GROUP I: Patients receive veliparib PO every 12 hours on days 1-4 and cyclophosphamide IV over 60 minutes on day 3.&#xD;
GROUP II: Patients receive veliparib PO every 12 hours on days 1-4, cyclophosphamide IV over 60 minutes on day 3, and doxorubicin hydrochloride IV over 15 minutes on day 3.&#xD;
GROUP III: Patients receive veliparib PO every 12 hours on days 1-7, cyclophosphamide IV over 60 minutes on day 1, and doxorubicin hydrochloride IV over 15 minutes on day 1.&#xD;
GROUP IV: Patients receive veliparib PO every 12 hours on days 1-14, cyclophosphamide IV over 60 minutes on day 1, and doxorubicin hydrochloride over 15 minutes on day 1.&#xD;
In all groups, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (veliparib, cyclophosphamide, doxorubicin)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamide Monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (veliparib, cyclophosphamide, doxorubicin)</arm_group_label>
    <other_name>5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)</other_name>
    <other_name>ADM</other_name>
    <other_name>Adriacin</other_name>
    <other_name>Adriamycin</other_name>
    <other_name>Adriamycin Hydrochloride</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
    <other_name>ADRIAMYCIN, HYDROCHLORIDE</other_name>
    <other_name>Adriamycine</other_name>
    <other_name>Adriblastina</other_name>
    <other_name>Adriblastine</other_name>
    <other_name>Adrimedac</other_name>
    <other_name>Chloridrato de Doxorrubicina</other_name>
    <other_name>DOX</other_name>
    <other_name>DOXO-CELL</other_name>
    <other_name>Doxolem</other_name>
    <other_name>Doxorubicin HCl</other_name>
    <other_name>Doxorubicin.HCl</other_name>
    <other_name>Doxorubin</other_name>
    <other_name>Farmiblastina</other_name>
    <other_name>FI 106</other_name>
    <other_name>FI-106</other_name>
    <other_name>hydroxydaunorubicin</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (veliparib, cyclophosphamide, doxorubicin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (veliparib, cyclophosphamide, doxorubicin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Veliparib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (veliparib, cyclophosphamide, doxorubicin)</arm_group_label>
    <other_name>ABT-888</other_name>
    <other_name>PARP-1 inhibitor ABT-888</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically confirmed malignancy that is metastatic or&#xD;
             unresectable and for which standard curative or palliative measures do not exist or&#xD;
             are no longer effective; patients with either solid tumors or non-Hodgkin's lymphoma&#xD;
             are eligible&#xD;
&#xD;
               -  At the recommended Phase II dose level, an additional 6 to 12 patients in each&#xD;
                  group with the following criteria will be enrolled: documented breast cancer&#xD;
                  (BRCA)1/BRC2 mutation, triple-negative breast cancer defined as estrogen receptor&#xD;
                  (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth&#xD;
                  factor receptor (HER)2-negative, or patients who would benefit from a&#xD;
                  cyclophosphamide-based regimen&#xD;
&#xD;
               -  On the schedule of ABT-888 given for 7 or 14 days, only patients with metastatic&#xD;
                  breast cancer will be enrolled&#xD;
&#xD;
          -  Patients must be &gt;= 4 weeks since prior chemotherapy or radiation therapy (&gt;= 6 weeks&#xD;
             if the last regimen included carmustine [BCNU] or mitomycin C); patients previously&#xD;
             treated with cyclophosphamide should not be necessarily excluded&#xD;
&#xD;
          -  Patients with non-Hodgkin's lymphoma that is amenable to hematopoietic stem cell&#xD;
             transplantation with curative intent may participate only if stem cell transplant is&#xD;
             refused or is not indicated&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2&#xD;
&#xD;
          -  Life expectancy of greater than 2 months&#xD;
&#xD;
          -  Hemoglobin &gt;= 9.0 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1,500/uL&#xD;
&#xD;
          -  Platelets &gt;= 100,000/uL&#xD;
&#xD;
          -  Total bilirubin within normal institutional limits&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) or&#xD;
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 2.5 X&#xD;
             institutional upper limit of normal (ULN), =&lt; 5 x ULN if known hepatic metastases&#xD;
&#xD;
          -  Creatinine within normal institutional limits OR creatinine clearance &gt;= 60&#xD;
             ml/min/1.73 m^2 for patients with creatinine levels above institutional normal&#xD;
&#xD;
          -  Prothrombin time (PT)/international normalized ratio (INR)/partial thromboplastin time&#xD;
             (PTT) =&lt; 1.2 X institutional ULN&#xD;
&#xD;
          -  Women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for&#xD;
             the duration of study participation; should a woman become pregnant or suspect she is&#xD;
             pregnant while participating in this study, she should inform her treating physician&#xD;
             immediately&#xD;
&#xD;
          -  Patients enrolled in a group where the treatment is adriamycin and cycloblastin (AC):&#xD;
             ejection fraction &gt;= 50% by multigated acquisition scan (MUGA) or echocardiogram&#xD;
&#xD;
          -  Patients must sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent administration of any other investigational agent(s)&#xD;
&#xD;
          -  Prior high-dose therapy requiring hematopoietic stem cell transplantation&#xD;
&#xD;
          -  Prior anti-cancer treatments involving radioactive pharmaceuticals&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to ABT-888 and/or cyclophosphamide&#xD;
&#xD;
          -  Patients receiving any medications or substances that are strong inhibitors or strong&#xD;
             inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP 3A4),&#xD;
             cytochrome P450, family 2, subfamily B, polypeptide 6 (2B6), cytochrome P450, family&#xD;
             2, subfamily C, polypeptide 9 (2C9) or cytochrome P450, family 2, subfamily C,&#xD;
             polypeptide 19 (2C19) are prohibited; at the time of screening, if the patient is&#xD;
             currently receiving any of the listed prohibited medication(s), the medication(s) must&#xD;
             be discontinued for a period of no less than 7 days prior to administration of the&#xD;
             first dose of study medication in order for the patient to meet study eligibility&#xD;
             except for the following substance where the washout should be 6 months: amiodarone&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements; New York Heart Association (NYHA) grade II or greater congestive&#xD;
             heart failure&#xD;
&#xD;
          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if&#xD;
             the mother is treated with ABT-888; these potential risks may also apply to other&#xD;
             agents used in this study&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral&#xD;
             therapy are ineligible; appropriate studies will be undertaken in patients receiving&#xD;
             combination antiretroviral therapy when indicated; NOTE: HIV seropositive patients not&#xD;
             receiving combination antiretroviral therapy who have cluster of differentiation (CD)4&#xD;
             cells &gt;= 350/mm^3, no opportunistic infections and meet all eligibility criteria may&#xD;
             participate in this study&#xD;
&#xD;
          -  Any condition (e.g., gastrointestinal tract disease resulting in an inability to take&#xD;
             oral medication or a requirement for IV alimentation, prior surgical procedures&#xD;
             affecting absorption, or active peptic ulcer disease) that impairs their ability to&#xD;
             swallow and retain ABT-888 capsules&#xD;
&#xD;
          -  Patients with gastrointestinal conditions that might predispose for drug&#xD;
             intolerability or poor drug absorption (e.g., inability to take oral medication or a&#xD;
             requirement for IV alimentation, prior surgical procedures affecting absorption,&#xD;
             malabsorption syndrome, active peptic ulcer disease) are excluded; subjects with&#xD;
             ulcerative colitis, inflammatory bowel disease, or a partial or complete small bowel&#xD;
             obstruction are also excluded&#xD;
&#xD;
          -  Patients with active central nervous system (CNS) metastases are excluded&#xD;
&#xD;
               -  Patients with CNS metastases that have been treated must be off steroid treatment&#xD;
                  for &gt; 3 months, be asymptomatic and off steroid treatment prior to study&#xD;
                  enrollment&#xD;
&#xD;
               -  Patients that have symptoms to suggest CNS metastases should have a brain&#xD;
                  magnetic resonance imaging (MRI) within 28 days of enrollment to confirm the&#xD;
                  absence of CNS metastases; contrast computed tomography (CT) is acceptable for&#xD;
                  patients who are unable to undergo a brain MRI&#xD;
&#xD;
          -  Patients with active seizure or a history of active seizure&#xD;
&#xD;
          -  Any other medical, social, or psychological condition that may significantly affect&#xD;
             safety and/or compliance&#xD;
&#xD;
          -  Patients enrolled in a group where treatment is AC: prior doxorubicin exposure of &gt;&#xD;
             300 mg/m^2 or equivalent anthracycline exposure (i.e., epirubicin dose &gt; 540 mg/m^2)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark N Stein</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers Cancer Institute of New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 22, 2008</study_first_submitted>
  <study_first_submitted_qc>August 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2008</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Veliparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

